New Study Projects Devastating Losses to Drug Develop., Jobs & Patient Health in Biopharma Ecosystem

Washington, DC – A new study estimates that there would be 237 fewer FDA approvals of new medicines for patients battling cancer, neurological, and rare and infectious diseases over the next decade as well as 1.1 million lost jobs if proposals to expand government-mandated drug pricing policies are implemented...